BridgeBio Pharma, Inc. BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

BBIO

Kedudukan dalam Saham #1620
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Harga Saham
$68.06
Modal Pasaran
$13.31B
Perubahan (1 hari)
2.52%
Perubahan (1 tahun)
23.93%
Negara
US
Perdagangan BridgeBio Pharma, Inc. (BBIO)

Kategori

Healthcare
Bilangan saham terbitan bagi BridgeBio Pharma, Inc. (BBIO)
Bilangan saham terbitan setakat June 2026: 195.79M
Menurut laporan kewangan terkini dan harga saham BridgeBio Pharma, Inc., bilangan saham terbitan semasa ialah 195.79M. Pada akhir December 2023, syarikat mempunyai 162.79M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk BridgeBio Pharma, Inc. (BBIO) dari 2017 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
2026 (TTM) 195.79M 5.22%
2024 186.08M 14.30%
2023 162.79M 10.39%
2022 147.47M 2.16%
2021 144.36M 22.34%
2020 118.00M 12.27%
2019 105.10M 13.83%
2018 92.33M 0.00%
2017 92.33M 0.00%
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 29.68%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 102.26%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 144.61%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -68.24%
NL